<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556617</url>
  </required_header>
  <id_info>
    <org_study_id>PLX124-04</org_study_id>
    <nct_id>NCT04556617</nct_id>
  </id_info>
  <brief_title>PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)</brief_title>
  <official_title>A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination With Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexxikon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Plexxikon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics&#xD;
      and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic&#xD;
      Castration-Resistant Prostate Cancer (mCRPC)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2a (both arms): Disease response as defined by at least one of the following: Objective response by modified RECIST v1.1, PSA response, or circulating tumor cell count (CTC) response.</measure>
    <time_frame>From 6 weeks of treatment (Cycle 3 Day 1; 21 days per cycle) until completion of long term follow-up, an average of 6 months.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b (both arms): Incidence of dose-limiting-toxicities (DLTs)</measure>
    <time_frame>From time of first dose of PLX2853 and combination agent(s) through completion of Cycle 1 (21 days).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b (both arms): Incidence of TEAEs that are related to treatment</measure>
    <time_frame>From time of first dose of PLX2853 and combination agent(s) until 30 days from end of treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression-free survival (rPFS) (both arms, both phases)</measure>
    <time_frame>From 6 weeks of treatment (Cycle 3 Day 1; 21 days per cycle) until completion of long term follow-up, an average of 6 months.</time_frame>
    <description>Radiographic progression-free survival (PFS) will be calculated for each subject as the number of days from the first day of PLX2853 and combination agent(s) treatment (Cycle 1 Day 1) to the date of the first documented disease progression by either RECIST v.1.1 or on bone scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression (both arms, both phases)</measure>
    <time_frame>From 3 weeks of treatment (Cycle 2 Day 1; 21 days per cycle) until completion of long term follow-up, an average of 6 months.</time_frame>
    <description>PSA progression (defined per PCWG3 as a ≥25% increase and an absolute increase of ≥2 ng/mL above the nadir, which is confirmed by a second consecutive value obtained 3 or more weeks later).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PSA Response (both arms, both phases)</measure>
    <time_frame>From 3 weeks of treatment (Cycle 3 Day 1; 21 days per cycle) until completion of long term follow-up, an average of 6 months.</time_frame>
    <description>Duration of PSA response will be calculated for each subject with a PSA response as the time from date of first documented, confirmed response (CR or PR) using PCWG3 until date of documented progression confirmed at least 3 weeks later, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (both arms, both phases)</measure>
    <time_frame>From time of first dose until completion of long term follow-up, approximately 30 months.</time_frame>
    <description>Overall survival (OS) will be calculated for each subject as the number of days from the first day of PLX2853 treatment and combination agent(s) (Cycle 1 Day 1) to the date of death from any cause. If a subject is lost to follow-up, OS is censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all TEAEs (both arms, both phases)</measure>
    <time_frame>From time of first dose of PLX2853 and combination agent(s) until 30 days from end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs that result in dose interruption, reduction or discontinuation (both arms, both phases)</measure>
    <time_frame>From time of first dose of PLX2853 and combination agent(s) until 30 days from end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PLX2853 PK parameter AUC0-24 (both arms, both phases)</measure>
    <time_frame>From time of first dose until 30 days from end of treatment.</time_frame>
    <description>AUC from time zero extrapolated to 24 hours (AUC0-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PLX2853 PK parameter Cmax (both arms, both phases)</measure>
    <time_frame>From time of first dose until 30 days from end of treatment.</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PLX2853 PK parameter T1/2 (both arms, both phases)</measure>
    <time_frame>From time of first dose until 30 days from end of treatment.</time_frame>
    <description>terminal elimination half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) (both arms, both phases)</measure>
    <time_frame>From 6 weeks of treatment (Cycle 3 Day 1; 21 days per cycle) until completion of long term follow-up, an average of 6 months.</time_frame>
    <description>Best Overall Response (BOR) per RECIST v1.1 will be calculated for each subject with a minimum interval for confirmation of CR and PR of 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) (both arms, both phases)</measure>
    <time_frame>From 6 weeks of treatment (Cycle 3 Day 1; 21 days per cycle) until completion of long term follow-up, an average of 6 months.</time_frame>
    <description>Time from date of first documented, confirmed response using RECIST v1.1 and PCWG3 until date of documented progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first Symptomatic Skeletal-Related Event (SSRE) (both arms, both phases)</measure>
    <time_frame>From time of first dose until 30 days from end of treatment.</time_frame>
    <description>Time to first Symptomatic Skeletal-Related Event (SSRE) defined as:&#xD;
Use of radiation therapy to prevent or relieve skeletal symptoms.&#xD;
Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). Radiologic documentation is required.&#xD;
Occurrence of spinal cord compression. Radiologic documentation required.&#xD;
Orthopedic surgical intervention for bone metastasis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>PLX2853 + Abiraterone Acetate + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 15 evaluable subjects with mCRPC will be enrolled.&#xD;
Phase 2a (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 19 evaluable subjects with mCRPC will be enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLX2853 + Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b (PLX2853 + Olaparib Combination): Up to 18 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled.&#xD;
Phase 2a (PLX2853 + Olaparib Combination): Up to 58 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX2853</intervention_name>
    <description>PLX2853 tablets</description>
    <arm_group_label>PLX2853 + Abiraterone Acetate + Prednisone</arm_group_label>
    <arm_group_label>PLX2853 + Olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Olaparib tablets</description>
    <arm_group_label>PLX2853 + Olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <description>Abiraterone acetate tablets</description>
    <arm_group_label>PLX2853 + Abiraterone Acetate + Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone (or equivalent) tablets</description>
    <arm_group_label>PLX2853 + Abiraterone Acetate + Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years at the time of signing informed consent.&#xD;
&#xD;
          2. Histologically confirmed adenocarcinoma of the prostate with tumor tissue available&#xD;
             for molecular analyses.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group Performance Status 0 to 1.&#xD;
&#xD;
          4. Adequate organ function as demonstrated following laboratory values.&#xD;
&#xD;
          5. Fertile male subjects with female sexual partners must agree to use a highly effective&#xD;
             method of birth control during the study and for 90 days after the last dose of study&#xD;
             drug.&#xD;
&#xD;
          6. Except as specified above for organ function, all drug-related toxicity from previous&#xD;
             cancer therapy (including ongoing Abiraterone Acetate + Prednisone therapy if&#xD;
             applicable) must be resolved (to Grade ≤1 or baseline per National Cancer Institute&#xD;
             Common Terminology Criteria for Adverse Events version 5.0) prior to study treatment&#xD;
             administration (Grade 2: alopecia, hot flashes, decreased libido, or neuropathy is&#xD;
             allowed).&#xD;
&#xD;
          7. Willingness and ability to provide written informed consent prior to any study-related&#xD;
             procedures and to comply with all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior exposure to a bromodomain inhibitor.&#xD;
&#xD;
          2. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.&#xD;
&#xD;
          3. Clinically significant cardiac disease.&#xD;
&#xD;
          4. Inability to take oral medication or significant nausea and vomiting, malabsorption,&#xD;
             or significant small bowel resection that, in the opinion of the Investigator, would&#xD;
             preclude adequate absorption.&#xD;
&#xD;
          5. Active known second malignancy with the exception of any of the following:&#xD;
&#xD;
               -  Adequately treated basal cell carcinoma or squamous cell carcinoma of the skin.&#xD;
&#xD;
               -  Adequately treated Stage I cancer from which the subject is currently in&#xD;
                  remission and has been in remission for ≥2 years.&#xD;
&#xD;
               -  Any other cancer from which the subject has been disease-free for ≥3 years.&#xD;
&#xD;
          6. Subject is participating in any other therapeutic clinical study (observational or&#xD;
             registry studies are allowed).&#xD;
&#xD;
          7. Presence of any other medical, psychological, familial, sociological, or geographic&#xD;
             condition potentially hampering compliance with the study protocol or would interfere&#xD;
             with the study endpoints or the subject's ability to participate in the study in the&#xD;
             judgment of the Investigator.&#xD;
&#xD;
          8. Receipt of any anti-cancer therapy prior to Cycle 1 Day 1 with less than protocol&#xD;
             defined wash-out with the exception of Abiraterone Acetate (for subjects enrolling&#xD;
             into Abiraterone Acetate Combination) and GnRH therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Watkins</last_name>
    <phone>510-647-4151</phone>
    <email>Pwatkins@plexxikon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Szmulewitz</last_name>
      <phone>773-834-3914</phone>
      <email>rszmulew@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Atchison</last_name>
      <phone>313-576-9014</phone>
      <email>atchisono@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nurse Navigator</last_name>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal Shore, MD</last_name>
      <phone>843-449-1010</phone>
      <email>nshore@auclinics.com</email>
    </contact>
    <investigator>
      <last_name>Neal Shore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology/ Sarah Cannon</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith McKean, MD</last_name>
      <phone>877-691-7274</phone>
      <email>asksarah@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialist</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Friedman, RN</last_name>
      <phone>703-208-3192</phone>
      <email>Carrie.Friedman@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Connect</last_name>
      <phone>608-262-5223</phone>
      <email>clinicaltrials@cancer.wisc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Fontana</last_name>
      <email>Elisa.Fontana@hcahealthcare.co.uk</email>
    </contact>
    <investigator>
      <last_name>Elisa Fontana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PLX2853</keyword>
  <keyword>Metastatic Castration-resistant Prostate Cancer</keyword>
  <keyword>Olaparib</keyword>
  <keyword>Abiraterone Acetate</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

